Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

FBI arrests Saudi OpenAI engineer over covert recording device, DOJ says

When AI becomes a security investigator: an incident at openai

OpenAI says it discovered a sophisticated recording device hidden inside one of its offices. According to the company, its AI models helped analyze the device and trace it to an employee who had allegedly planted it days earlier.

OpenAI referred the matter to the FBI. The employee was terminated, and an arrest was made. The investigation remains ongoing.

Importantly, OpenAI says it has found no indication so far that the individual improperly accessed or exfiltrated model weights, source code, or customer data.

Beyond the incident itself, there is an intriguing development: AI is being used not just to build increasingly powerful systems, but also to investigate sophisticated security threats—including potential insider threats.

It also brings to mind AI 2027, the scenario-based forecast exploring how rapidly advancing AI could reshape technology, security, and society. Some of its concerns about the security challenges facing frontier AI labs may feel increasingly relevant, although this incident alone does not validate the scenario’s broader predictions.

The bigger question is not simply how powerful AI will become, but whether the organizations developing it can secure their people, facilities, intellectual property, and infrastructure as quickly as their technology advances.

Metacognition: Learning the Structure of Scientific Judgment

Can AI learn not just how to do science, but how to judge what to do next?

Scientific discovery is not simply a matter of generating ideas or finding answers. Researchers must know when to explore new possibilities, when to follow a systematic procedure, and when to stop and reassess their conclusions in light of new evidence. Yet most AI models are trained primarily on the products of scientific work—papers, findings, and solutions—rather than the decision-making processes that guide researchers through uncertain, long-term investigations. https://arxiv.org/abs/2609.

This study introduces Metacognitive Steering, a technique designed to help AI models shift between different modes of scientific reasoning. By analyzing real interactions from scientific research, the researchers identified internal structures within Kimi 2.6, a trillion-parameter mixture-of-experts model, that could be used to influence how it reasons. Rather than retraining the model or changing its parameters, the method applies targeted interventions during inference to encourage exploration, systematic execution, or critical reassessment, depending on what the situation requires.

The researchers report that this approach led to more sustained exploration, more explicit elimination of unpromising possibilities, and conclusions that responded more carefully to evidence. They also incorporated the technique into Columbus-1, an autonomous research system that reportedly identified eight security vulnerabilities in BlueZ, a Bluetooth software stack, which were independently reproduced and could be reached by an attacker. In another demonstration, the system directed the design, simulation, and fabrication of a ten-foot rocket intended to perform a propulsive landing using solid motors that cannot be throttled.

The broader significance is that AI reasoning may be improved not only by making models larger or giving them more information, but also by learning how to regulate their own problem-solving strategies. If further validated, this approach could help AI systems conduct longer, more disciplined investigations instead of simply pursuing an initial idea or producing a plausible answer.

However, these demonstrations should be interpreted carefully. Identifying vulnerabilities and coordinating a rocket-development process are notable engineering achievements, but they do not, by themselves, establish that an AI system possesses human-like metacognition or can independently conduct reliable scientific discovery across domains. The important question is whether this steering method consistently improves the quality, reliability, and reproducibility of research compared with existing approaches.

#ArtificialIntelligence #metacognition #ScientificDiscovery #AIagents.

🧠 METACOGNITION: LEARNING THE STRUCTURE OF SCIENTIFIC JUDGMENT

Vikings Reached North America 500 Years Before Columbus, Archaeology Confirms

Medieval Icelandic sagas describe journeys west from Greenland, including voyages associated with Leif Erikson and a region called Vinland. The settlement supports the broader accounts of Norse travel, but archaeologists cannot confirm that Leif himself stayed there. Nor can they establish how many expeditions reached the coast.

Ancient settlement reveals clues about Norse exploration and indigenous contact

Butternuts found at the settlement offer another clue. Because the trees do not grow naturally in Newfoundland, Parks Canada says the finds suggest travel farther south or contact with Indigenous trading networks.

Blocking a protein may reduce buildup of harmful aging cells

A team led by Cedars-Sinai Health Sciences University investigators has identified a protein that may hide aging cells from the body’s immune system, allowing them to build up and contribute to age-related health problems.

The findings, published in Cell Metabolism, suggest that the protein, called PD-L2, could serve as a target for treatments designed to remove harmful aging cells or as a blood marker that helps researchers track them.

“Our findings suggest that PD-L2 may help aging cells stay in the body when they would normally be removed by the immune system,” said Selim Chaib, Ph.D., research assistant professor of medicine at Cedars-Sinai and first and co-corresponding author of the study.

Age-Based Testing Misses Most With Inherited Cancer Risk

Restricting germline genetic testing to patients diagnosed with cancer before age 50 may miss the large majority of all those with inherited pathogenic variants, a new study suggested.

The research, based on germline sequencing of 39,184 unselected patients with solid tumors, found that the age-50 cutoff would miss 72% of all patients harboring a pathogenic variant. That included 68% of those with moderate-or high-penetrance variants, which confer substantially elevated lifetime cancer risks.

“Hereditary cancer can occur at any age, and we should move toward a new standard in which genetic testing is considered for every patient diagnosed with cancer, regardless of age,” said lead study author Zsofia K. Stadler, MD, of Memorial Sloan Kettering (MSK) Cancer Center in New York City.

Fyn kinase: a key mechanistic regulator and therapeutic target in tauopathy and neurodegenerative diseases

Synaptic dysfunction and intracellular accumulation of pathological tau are convergent hallmarks of Alzheimer’s disease (AD) and related tauopathies, yet the molecular mechanisms coupling these events to widespread neurodegeneration remain incompletely understood. The Src family kinase Fyn has emerged as a critical signaling hub that integrates upstream pathogenic triggers, such as amyloid-β (Aβ), with downstream neurotoxic cascades. Here, we review the multifaceted roles of Fyn in orchestrating synaptic failure, highlighting how Fyn recruitment by mislocalized tau promotes N-methyl-D-aspartate receptor hyperactivation and calcium dysregulation. We examine the biophysical basis of Fyn–tau interactions, particularly the role of liquid–liquid phase separation in stabilizing toxic signaling complexes. We also discuss how aberrant Fyn signaling in microglia and astrocytes amplifies neuroinflammation. Finally, we evaluate the potential of Fyn as a therapeutic target, emphasizing the necessity of strategies that selectively uncouple pathological signaling from physiological functions to effectively halt disease progression.

Prevalence and characteristics of patients with coronary heart disease and blood pressure below target: the INTERASPIRE study

Background Despite treatment, many hypertensive patients with coronary heart disease (CHD) have blood pressure (BP) that remains above guideline targets. However, less is known about patients in whom on-treatment BP is below target and major European guidelines differ substantially in their recommendations for such patients. Specifically, 2023 European Society of Hypertension (ESH) guidelines provide a Class 3 recommendation to proactively avoid BP below target whereas 2024 European Society of Cardiology (ESC) guidelines do not.

Methods Between 2020 and 2023, adults hospitalised in the previous 6–24 months with incident or recurrent CHD were sampled in 14 countries from all six WHO regions and invited for a standardised interview and examination as part of the International Action on Secondary and Primary Prevention by Intervention to Reduce Events (INTERASPIRE) study. We measured seated BP twice using an automated oscillometric device after 5 min of rest. We defined participants as having BP above target (BP ≥130/80 mm Hg), at target (BP 120–129/70–79 mm Hg) or below target (120÷70 mm Hg); according to both 2023 ESH and 2024 ESC guidelines.

Results Among 4,548 participants (21.1% female), the mean age (±SD) was 60.0 (±10.3) years. At a median (IQR) of 1.05 (0.76–1.45) years after index CHD hospitalisation, 10.3% of patients had BP readings within the target range of 120–129/70–79 mm Hg, with 53.9% above target and 35.7% below target. Patients with below-target BP were more likely to have heart failure (13.6% vs 10.0%, p=0.041) and estimated glomerular filtration rate 60 mL/min/1.73 m² (18.9% vs 10.7%, p0.001), when compared with those at target. They were also statistically more likely to be severely frail (p=0.030). The median number of BP-lowering medications did not differ significantly between the 3 BP target groups. Cumulative dosing of BP-lowering medications in the below-target group was also not more intensive than that in the at-target group.

Nanoparticle injection reprograms NK immune cells to fight cancer and autoimmune disorders

MIT engineers have developed a new way to program natural killer (NK) immune cells to target cancerous T cells or T cells that have become autoreactive, leading to diseases such as lymphoma and autoimmune hepatitis.

Using their new technique, the researchers can reprogram NK cells to target diseased T cells without ever removing the NK cells from the patient’s body. Instead, they use lipid nanoparticles to deliver messenger RNA directly to NK cells. These mRNA molecules encode proteins that allow the NK cells to seek and destroy the dysfunctional T cells.

Known as CAR NK cells, these cells could be deployed against a variety of diseases. The MIT team’s new approach could bypass one of the major obstacles to using these cells, which is the time and expense of manufacturing them outside the body.

/* */